The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer
Open Access
- 3 October 2023
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (19) , 19656-19666
Abstract
Background Notwithstanding that the past decade has witnessed unprecedented medical progress, gastric cancer (GC) remains a leading cause of cancer death, highlighting the need for effective prognostic markers. The Memorial Sloan Kettering Prognostic Score (MPS) has been validated as a valuable prognostic tool for patients with metastatic pancreatic adenocarcinoma (mPDAC). This study aimed to assess the prognostic value of the MPS in advanced GC.Methods Data from 367 patients were analyzed in the present study. The MPS for each patient was calculated based on the sum of scores based on the neutrophil-to-lymphocyte ratio and serum albumin levels. Multivariate analyses were performed to identify the independent clinicopathological parameters associated with overall survival (OS). Further subgroup analyses based on clinicopathological features were conducted.Results Patients with MPS 0 (n = 161), MPS 1 (n = 158), and MPS 2 (n = 48) exhibited significantly different OS, with a median survival duration of 20.7 (95%CI: 12.2-29.2), 14.9 (95%CI: 12.5-17.3), and 12.7 (95%CI: 9.3-16.0) months, respectively (p < 0.001). Significant differences in survival were observed among different groups of patients receiving chemotherapy (18.5 months vs. 14.7 months vs. 11.0 months, p = 0.03) or the subgroup receiving chemotherapy plus immunotherapy as first-line treatment (32.6 months vs. 17.7 months vs. 12.7 months, p = 0.02). The MPS was identified as an independent prognostic factor in multivariate analysis. During subgroup analyses, MPS-low (MPS 0) was consistently associated with a better prognosis than MPS-high (MPS 1 or 2).Conclusions MPS is a practical, simple, and useful prognostic tool for patients with advanced GC. Further studies are warranted to validate its prognostic value in advanced GC.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LQ19H160031)
This publication has 43 references indexed in Scilit:
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?Science, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literatureNutrition Journal, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Expression of Interleukin-1 Receptor–Associated Kinase-1 in Non–Small Cell Lung Carcinoma and Preneoplastic LesionsClinical Cancer Research, 2010
- Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemiaBlood, 2009
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and LymphomasCancer Research, 2009
- Cancer-related inflammationNature, 2008
- Inflammation and cancerNature, 2002